Karyopharm Therapeutics Inc. Files Definitive Proxy Statement

TL;DR

<b>Karyopharm Therapeutics Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023, detailing executive compensation and award valuations.</b>

AI Summary

Karyopharm Therapeutics Inc. (KPTI) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Karyopharm Therapeutics Inc. filed a Definitive Proxy Statement (DEF 14A) on April 19, 2024. The filing pertains to the fiscal year ending December 31, 2023. The company's principal executive offices are located at 85 Wells Avenue, Second Floor, Newton, MA 02459. The filing includes information related to executive compensation, specifically the fair value of awards granted and outstanding. The report covers changes in the fair value of awards for members such as Mr. Paulson and Dr. Kauffman.

Why It Matters

For investors and stakeholders tracking Karyopharm Therapeutics Inc., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and the valuation of stock and option awards, which can impact company performance and shareholder returns. Shareholders will use this information to make informed voting decisions on executive compensation and other matters presented at the upcoming shareholder meeting.

Risk Assessment

Risk Level: low — Karyopharm Therapeutics Inc. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard disclosure practices rather than immediate company-specific events.

Analyst Insight

Review the executive compensation details and award valuations to assess alignment with company performance and shareholder interests.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting Period)
• 2024-04-19 — Filing Date (DEF 14A Submission)

Key Players & Entities

• Karyopharm Therapeutics Inc. (company) — Registrant
• 85 WELLS AVENUE (location) — Business Address
• NEWTON (location) — Business Address City
• MA (location) — Business Address State
• 02459 (location) — Business Address ZIP
• Mr. Paulson (person) — Executive
• Dr. Kauffman (person) — Executive

FAQ

Industry Context

Karyopharm Therapeutics Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing novel treatments.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

What Investors Should Do

1. Analyze the disclosed executive compensation packages for alignment with company performance.
2. Evaluate the fair value of stock and option awards granted to key executives.
3. Understand any proposals or voting matters presented to shareholders in the proxy statement.

Key Dates

• 2024-04-19: Filing of Definitive Proxy Statement — Provides details on executive compensation and shareholder matters for the fiscal year ending 2023-12-31.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure for public companies regarding their annual shareholder meetings and executive compensation.

Filing Documents

• kpti-20240417.htm (DEF 14A) — 2293KB
• img95390205_0.jpg (GRAPHIC) — 33KB
• img95390205_1.jpg (GRAPHIC) — 9KB
• img95390205_2.jpg (GRAPHIC) — 33KB
• img95390205_3.jpg (GRAPHIC) — 112KB
• img95390205_4.jpg (GRAPHIC) — 241KB
• img95390205_5.jpg (GRAPHIC) — 212KB
• img95390205_6.jpg (GRAPHIC) — 228KB
• img95390205_7.jpg (GRAPHIC) — 402KB
• img95390205_8.jpg (GRAPHIC) — 365KB
• 0000950170-24-045717.txt (&nbsp;) — 7113KB
• kpti-20240417.xsd (EX-101.SCH) — 29KB
• kpti-20240417_htm.xml (XML) — 161KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 60 Compensation Discussion and Analysis 60 Tax and Accounting Considerations 72 Hedging and Pledging Policy 72 Compensation Recovery ("Clawback") Policy 72 Compensation Committee Report 72 2023 Summary Compensation Table 73 Grants of Plan-Based Awards in 2023 74 Outstanding Equity Awards at December 31, 2023 75 Option Exercises and Stock Vested in 2023 76 Table of Contents Employment, Severance and Change in Control Arrangements 76 Potential Payments Upon Termination or Change in Control 78 CEO Pay Ratio 80 Pay Versus Performance 81 2023 Performance Measures 83 Relationships Between Compensation Actually Paid to our NEOs and Performance Measures 83 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 85 Equity Compensation Plan Information 85 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 86 Related Person Transactions 86 Policies and Procedures for Related Person Transactions 86 PROPOSAL 6: RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 88 Independent Registered Public Accountant Fees 88 Pre-Approval Policies and Procedures 89

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 90 DELINQUENT SECTION 16(a) REPORTS 92 STOCKHOLDER PROPOSALS 92 STOCKHOLDERS SHARING THE SAME ADDRESS 93 INCORPORATION BY REFERENCE 93 OTHER MATTERS 93 APPENDIX A: Amendment to 2022 Equity Incentive Plan, As Amended A- 1 APPENDIX B: Amendment to Amended & Restated 2013 Employee Stock Purchase Plan B- 1 Table of Contents PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, MAY 29, 2024 The Board of Directors (the "Board") of Karyopharm Therapeutics Inc. (which we also refer to as "Karyopharm," "the Company," "we," "us," or "our") is soliciting proxies for use at the 2024 Annual Meeting of Stockholders (the "Annual Meeting"), to be held exclusively online via the Internet as a virtual web conference at www.virtualshareholdermeeting.com/KPTI2024 on Wednesday, May 29, 2024 at 9:00 a.m. Eastern Time. We have determined that the Annual Meeting will be held in a virtual meeting format only, via the Internet, with no physical in-person meeting. At our virtual Annual Meeting, stockholders will be able to attend, vote and submit questions by visiting www.virtualshareholdermeeting.com/KPTI2024 . Further information about how to attend the Annual Meeting online, vote your shares online during the Annual Meeting and submit questions during the Annual Meeting is included in this proxy statement. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on Wednesday, May 29, 2024: This proxy statement and our annual report are available electronically at www.proxyvote.com . On or about April 19, 2024, we will begin mailing a Notice of Internet Availability of Proxy Materials ("Notice") to our stockholders (other than those who previously requested electronic or paper delivery of proxy materials), directing stockholders to a website where they can access our proxy materials, including this p

View Full Filing

View this DEF 14A filing on SEC EDGAR